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It is well known that Streptococcus pneumoniae remains a lead-ing cause of childhood mortality; in 2008, it was estimated to be 
responsible for over 500,000 deaths in children aged 1–59 months.1 
It is also known that the pneumococcus is a cause of significant 
morbidity and mortality among those younger and older than the 
1- to 59-month age group,2,3 although prevention of disease in these 
age groups has not been the target of global efforts to date. Serious 
diseases caused by the pneumococcus across all age groups include 
pneumonia, meningitis and sepsis. Developing countries, mostly in 
Africa and Asia, carry the highest burden of both pneumococcal dis-
ease incidence and mortality in children; this burden is measured 
both in terms of rates and absolute numbers of cases and deaths.1
effective vaccines to prevent pneumococcal disease in chil-
dren exist; access to these life-saving pneumococcal conjugate 
vaccines (pCV) has become possible in many developing coun-
tries through the focused, coordinated efforts of the GAVI Alli-
ance, including all of the key Alliance partners. the World Health 
Organization, the technical partner that provides global vaccine 
policy recommendations, advises that pCV be a part of the routine 
infant vaccine schedule for all countries, but particularly those with 
highest infant mortality rates and death counts.4 As of December 
2012, 87 countries had introduced pCV into their routine immu-
nization schedule (including a ceremonial launch in 1 country), of 
which 24 were GAVI-eligible countries.5,6 An additional 27 GAVI-
eligible countries are approved for introduction of pCV in 2013 
and beyond. pCVs are being implemented globally, including the 
poorest countries of the world, at a pace exceeding that of other pre-
viously developed vaccines. these vaccines were designed to pre-
vent pneumococcal disease in infants and toddlers, age groups for 
which previous pneumococcal vaccines were insufficiently protec-
tive. the introduction of pCV has been associated with a dramatic 
decline in pneumococcal disease caused by serotypes included in 
the vaccine (ie, vaccine-type disease), in children targeted for vac-
cination and older persons not intended for vaccination (the indirect 
effect of vaccination).7–16 the indirect effect on disease results from 
the impact of pCVs on preventing nasopharyngeal colonization.17 
Reduced colonization leads to reduced spread of the pneumococcus 
and thus less disease in the unimmunized.18
to assure that the enormous investments being made in 
pCV achieve the greatest disease impact, we must move beyond 
gross metrics of counting the number of countries introducing the 
vaccines. the focus should now be on achieving optimal vaccine 
implementation, including but not limited to optimizing vaccine 
coverage, in all countries. As important as targets are for achieving 
timely and thorough vaccine coverage, this is an intermediate goal 
and not the end goal, which is disease prevention and mortality 
reduction. toward that goal, we must understand the relationships 
between dosing schedules, measuring and understanding the mag-
nitude of change in disease, colonization and pathogen characteris-
tics with the intention and focus on achieving the greatest disease 
impact of the vaccine programs.
Vaccine delivery policy decision makers in countries, regions 
and globally must be able to include in their assessments evidence 
for how to administer these products to achieve maximal and optimal 
impact of the doses being administered and resources expended. this 
evidence should include the disease impact on both the age groups 
intended for vaccination and those who are not eligible for vaccina-
tion (ie, younger or older than the immunization age group). Impact 
in both groups contributes to the overall effect and therefore the 
assessment of return on investment in the health of the population as a 
whole. A variety of pCV immunization schedules have been assessed 
in controlled trials and in observational studies for a wide range of 
disease and pathogen outcomes. exactly which of these schedules 
are preferred over others, if there is any preference to be made, has 
not been not fully understood and therefore recommendations on pre-
ferred schedules cannot be made to the policy decision makers.
We therefore undertook a comprehensive, systematic assess-
ment of the absolute and relative benefit of pCV schedules to estab-
lish if there is evidence of preferred or sub-optimal schedules and 
to identify where essential gaps in knowledge lie so that targeted, 
strategic studies can be planned to assure a decisive evidence base 
for dosing schedule optimization. As with any vaccine, a limited 
number of randomized controlled trials have been conducted and 
these cannot answer the diverse range of biologic questions about 
dosing schedules. We therefore undertook this assessment putting 
together all of the evidence in the literature, with controlled trials 
and observational studies alike, aiming to be as inclusive as pos-
sible since the largest body of evidence would reveal a consistency 
in lessons learned even if any given trial was not the optimal study.
there are important factors to consider when weighing the 
benefits of different schedules. From an epidemiologic standpoint, 
it is important to account for differences in organism transmission 
dynamics in various geographic, disease burden and community 
settings; concluding that an introduction and dosing schedule are 
optimal should consider both the direct and indirect effects of the 
vaccine and will be influenced by the existing transmission and car-
riage rates in the community. From a policy standpoint, the deciding 
factors for a country should also take into account programmatic 
considerations for integrating pCV into existing vaccine schedules 
and the need to maximize limited financial resources. the perfor-
mance of the vaccine program to deliver high coverage at each time 
point in the immunization schedule will likely strongly influence 
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decision making regarding pCV schedule choice since ultimately 
delivering all the doses in a schedule is likely to outweigh any rela-
tive benefit of one schedule over another.
Furthermore, as infant vaccine schedules become increas-
ingly crowded, it is essential to integrate new products into existing 
schedules so that parents and caretakers will not be burdened by 
making additional visits; this must be weighed against the accept-
ability of multiple injections at a single visit and against the disease 
epidemiology across age strata.19 In many european countries, a 
2+1 schedule with doses at 3, 5 and 12 months coordinates well 
with existing schedules whereas a 3+1 schedule at 2, 4, 6 and 12 
months fits into the current uS immunization schedule.7,13,14 most 
developing countries have adopted a 3+0 schedule (6, 10 and 14 
weeks) as this fits well with the expanded programme on Immuni-
zations that is the standard WHO platform for core vaccine deliv-
ery.20 the degree to which a preference among these schedules 
exists as measured by disease and colonization impact is the pur-
pose of this systematic assessment. We approached the review with 
a series of policy questions (table 1) serving as guiding principles 
behind the methods, analysis and conclusions. We aimed to have as 
much methodological consistency across the outcomes as possible 
while maintaining the most inclusive principles for any given anal-
ysis. therefore, each outcome has been customized to the degree 
necessary to assure that the largest set of data is considered to 
inform the analysis and conclusions. these findings were reviewed 
at a meeting of experts held by WHO,21 subsequently presented to 
the WHO Strategic Advisory Group of experts on Immunizations 
in november 2011,22 and are now provided here in this supplement.
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TABLE 1. Policy Directed Questions That Guided the 
PCV Dosing Landscape Analysis Project
Dosing Issue Specific Questions
Number of doses in 
primary series
Is there evidence that a 3-dose primary series is 
superior or inferior to a 2-dose primary series?
Timing of primary 
series
Given a 3-dose schedule, is there evidence that 
it should be administered on a 2 + 1 or on a 
3 + 0 schedule?
What interval of PCV doses should be recom-
mended?
Is there evidence for guiding the optimal age 
for initiating PCV dosing?
Booster dose Is there evidence that a schedule including 
a booster dose is superior to one without a 
booster dose?
Indirect effects Do certain dosing schedules result in greater 
indirect impact (ie, reduction of vaccine-type 
disease among unimmunized age strata)?
